Residual Hepatic HCV-RNA in the Native Liver of Living Donor Liver Transplant Recipients with Chronic Hepatitis C: Mini-Review

Shu Hsien  Lin; Chih Chi  Wang; Kuang Tzu  Huang; Kuang Den  Chen; Chih Che  Lin; Li Wen  Hsu; King Wah  Chiu

Residual Hepatic HCV-RNA in the Native Liver of Living Donor Liver Transplant Recipients with Chronic Hepatitis C: Mini-Review

Shu Hsien Lin^1,², Chih Chi Wang^2,³^*, Kuang Tzu Huang^2,⁴, Kuang Den Chen^2,⁴, Chih Che Lin^2,³, Li Wen Hsu² and King Wah Chiu^1,^2,³^*: ¹Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; ²Liver Transplantation Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; ³Department of Surgery, College of Medicine, Chang Gung University, Taoyuan, Taiwan; ⁴Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

^*Corresponding Author (s) : Prof. Chih Chi Wang, Liver Transplantation Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Tel: +886-7-731-7123 Exn. 8301, Fax: +886-7-733-6856, Email: c471026@ms6.hinet.net

Prof. King Wah Chiu, Liver Transplantation Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Tel: +886-7-731-7123 Exn. 8301, Fax: +886-7-733-6856, Email: ufel4996@ms26.hinet.net

Received Date: Sep 08, 2021 / Published Date: Sep 12, 2022

Abstract

Chronic Hepatitis C Virus (HCV) infection is the leading risk factor for Hepatocellular Carcinoma (HCC), with an annual HCC risk of 2%-4% in cirrhotic patients. With the highly effective and safe direct-acting antiviral (DAA) therapy, HCV infection would be considered “cured and eliminated” successfully in >95% treated patients. However, even with the widespread use of direct-acting antivirals, Living Donor Liver Transplantation (LDLT) plays an important role in advanced liver disease. According to our recent observation, the pre-transplant serum HCV RNA levels may give an underestimate of the number of positive HCV RNA cases and that hepatic HCV RNA data may be more accurate.

Herein, we would like to have a mini review to detailed address issues including the significance of hepatic HCV RNA and the discrepancy between hepatic HCV RNA and HCV core antigen in native liver of chronic hepatitis C recipients undergoing LDLT, a new insight into cure and complete elimination of HCV infection and the utilization of HCV-aviremic organs into aviremic recipients in liver transplantation.

Keywords: Hepatitis C virus; Hepatocellular carcinoma; HCV RNA; Direct-acting antiviral agents; Liver transplantation

View PDF Download PDF

Citation: Lin SH, Wang CC, Huang KT, Chen KD, Lin CC (2021) Residual Hepatic HCV-RNA in the Native Liver of Living Donor Liver Transplant Recipients with Chronic Hepatitis C: Mini-Review. J Oncol Res Treat 6:167.

Copyright: © 2021 Lin SH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

黑料网

Journal of Oncology Research and Treatment
黑料网